ViiV HIV prevention trial stopped early on efficacy
ViiV said cabotegravir was found to be 69% more effective at preventing HIV acquisition than daily oral PrEP with emtricitabine/tenofovir disoproxil (FTC/TDF)
Read More
Tag: prep
PrEP to be available in England from April
Local authorities will receive £16 million in 2020 to 2021 to deliver the preventative HIV treatment.
Read More
PreP Impact trial to double in size
Speed of recruitment and demand for a trial assessing the impact of HIV prevention therapy PrEP has significantly exceeded initial predictions, leading researchers to consider increasing the number of participants from 13,000 to up to 26,000.
Read More
ViiV trials drug for HIV prevention in women
ViiV Healthcare has initiated a Phase III study exploring the efficacy of long-acting cabotegravir for the prevention of HIV infection in sexually active women.
Read More
National PreP service would be cost effective, research finds
Providing pre-exposure prophylaxis (PrEP) treatment to men who have sex with men at high risk of contracting HIV in England would be cost-effective and could prevent 25 percent of cases of infection, according to UCL research.
Read More
NHS England launches trial to assess PrEP
NHS England has kicked off what it claims to be the world’s largest single trial assessing the full impact of a scheme that gives patients at high risk of contracting HIV drugs to prevent infection.
Read More
NHS England to fund HIV prevention programme
NHS England has announced that it will fund a “major extension” of Public Health England’s HIV prevention programme to help reduce the incidence of the disease across the country.
Read More
Court rules that NHS England can fund HIV PReP
The Court of Appeal has ruled that NHS England does indeed have the legal power to fund what campaigners refer to as a “game-changing” drug to prevent the transmission of HIV under a strategy called Pre-Exposure Prophylaxis (PrEP).
Read More
EU clear’s Gilead’s Truvada for HIV PrEP
European regulators have issued a green light for the use of Gilead’s Truvada to cut the risk of HIV infection in adults.
Read More
NHS England launches consultation on HIV PrEP
NHS England has today launched a 45-day public consultation on a proposed clinical commissioning policy on Pre-Exposure Prophylaxis (PrEP) for HIV.
Read More
HIV campaigners win round in battle for HIV PrEP
The High Court in England has ruled that NHS England can indeed fund what campaigners are calling a “game-changing” drug that prevents the transmission of HIV, after health chiefs tried to ditch responsibility for commissioning the service.
Read More
AIDS charity gears up to challenge NHS England in court
The National AIDS Trust (NAT) is gearing up to fight in court a decision by NHS England to remove prophylactic HIV treatment PrEP from the official NHS commissioning process.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
